Publications by authors named "Shigeki Seto"

Claim this Profile
D
Discovery of Novel Bicyclic Pyrazoles as Potent PIP5K1C Inhibitors.
Koji Ochiai, Shigeki Seto, Masanobu Yajima, Ryosuke Namie, Noriaki Hashimoto

ACS Med Chem Lett· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of benzo[f]pyrido[4,3-b][1,4]oxazepin-10-one derivatives as orally available bromodomain and extra-terminal domain (BET) inhibitors with efficacy in an in vivo psoriatic animal model.
Masanori Sato, Takekazu Kondo, Yasushi Kohno, Shigeki Seto

Bioorg Med Chem· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of novel pyrazolo[1,5-a]pyridine-based EP receptor antagonists by scaffold hopping: Design, synthesis, and structure-activity relationships.
Yosuke Nishigaya, Kentaro Umei, Yoshifumi Saito, Hiroyuki Watanabe, Tatsuhiro Kondo, Shigeki Seto

Bioorg Med Chem Lett· September 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification of novel 1,2,3,6-tetrahydropyridyl-substituted benzo[d]thiazoles: Lead generation and optimization toward potent and orally active EP receptor antagonists.
Kentaro Umei, Yosuke Nishigaya, Kazuya Tatani, Yasushi Kohno, Nobuyuki Tanaka, Shigeki Seto

Bioorg Med Chem· July 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Novel pyrazolo[1,5-a]pyridines as orally active EP receptor antagonists: Synthesis, structure-activity relationship studies, and biological evaluation.
Kentaro Umei, Yosuke Nishigaya, Atsushi Kondo, Kazuya Tatani, Nobuyuki Tanaka, Shigeki Seto

Bioorg Med Chem· May 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Q
Quinolone derivatives containing strained spirocycle as orally active glycogen synthase kinase 3β (GSK-3β) inhibitors for type 2 diabetics.
Shigeki Seto, Kazuhiko Yumoto, Kyoko Okada, Yoshikazu Asahina, Aya Iwane

Bioorg Med Chem· February 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Synthesis and structure-activity relationship of 4-quinolone-3-carboxylic acid based inhibitors of glycogen synthase kinase-3β.
Oana M Cociorva, Bei Li, Tyzoon Nomanbhoy, Qiang Li, Ayako Nakamura, Shigeki Seto

Bioorg Med Chem Lett· October 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Design, synthesis, and structure-activity relationship studies of novel 2,4,6-trisubstituted-5-pyrimidinecarboxylic acids as peroxisome proliferator-activated receptor gamma (PPARgamma) partial agonists with comparable antidiabetic efficacy to rosiglitazone.
Shigeki Seto, Kyoko Okada, Koichi Kiyota, Shigeki Isogai, Maki Iwago

J Med Chem· July 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Total synthesis of vinblastine, vincristine, related natural products, and key structural analogues.
Hayato Ishikawa, David A Colby, Shigeki Seto, Porino Va, Annie Tam

J Am Chem Soc· April 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Analysis of crucial structural requirements of 2-substituted pyrimido[4,5-b][1,5]oxazocines as NK(1) receptor antagonist by axially chiral derivatives.
Shigeki Seto, Jun Asano

Bioorg Med Chem· August 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Design, synthesis, and evaluation of novel 2-substituted-4-aryl-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,5]oxazocin-5-ones as NK1 antagonists.
Shigeki Seto, Asao Tanioka, Makoto Ikeda, Shigeru Izawa

Bioorg Med Chem· October 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Design and synthesis of novel 9-substituted-7-aryl-3,4,5,6-tetrahydro-2H-pyrido[4,3-b]- and [2,3-b]-1,5-oxazocin-6-ones as NK(1) antagonists.
Shigeki Seto, Asao Tanioka, Makoto Ikeda, Shigeru Izawa

Bioorg Med Chem Lett· March 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
2
2-substituted-4-aryl-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,5]oxazocin-5-one as a structurally new NK1 antagonist.
Shigeki Seto, Asao Tanioka, Makoto Ikeda, Shigeru Izawa

Bioorg Med Chem Lett· March 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis